Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06093594
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-10-16
Brief Title:
Investigating Participation Patterns Among Stage IV Melanoma Patients
Sponsor:
Power Life Sciences Inc
Organization:
Power Life Sciences Inc
Study Overview
Official Title:
Understanding Patient Engagement Trends in Stage IV Melanoma Clinical Trials
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinical trials specifically focused on stage IV melanoma are crucial in assessing the safety and efficacy of new treatments for this disease These trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies providing compelling evidence to support wider implementation
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients
The main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None